Department of Respiratory Medicine, Academic Medical Centre, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
Thorax. 2011 Oct;66(10):910-7. doi: 10.1136/thx.2010.153643. Epub 2010 Nov 23.
Patients with severe refractory asthma pose a major healthcare problem. Over the last decade it has become increasingly clear that, for the development of new targeted therapies, there is an urgent need for further characterisation and classification of these patients. The Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) consortium is a pan-European public-private collaboration funded by the European Commission Innovative Medicines Initiative of the European Union. U-BIOPRED aims to subphenotype patients with severe refractory asthma by using an innovative systems biology approach. This paper presents the U-BIOPRED international consensus on the definition and diagnosis of severe asthma, aligning the latest concepts in adults as well as in children. The consensus is based on existing recommendations up to 2010 and will be used for the selection of patients for the upcoming U-BIOPRED study. It includes the differentiation between 'problematic', 'difficult' and 'severe refractory' asthma, and provides a systematic algorithmic approach to the evaluation of patients presenting with chronic severe asthma symptoms for use in clinical research and specialised care.
严重难治性哮喘患者是一个主要的医疗保健问题。在过去的十年中，越来越明显的是，为了开发新的靶向治疗方法，迫切需要进一步对这些患者进行特征描述和分类。非偏见生物标志物在预测呼吸系统疾病结果（U-BIOPRED）联盟是一个由欧盟欧洲委员会创新药物倡议资助的泛欧公私合作组织。U-BIOPRED 旨在通过创新的系统生物学方法对严重难治性哮喘患者进行亚表型分析。本文提出了 U-BIOPRED 对严重哮喘的定义和诊断的国际共识，该共识将成人和儿童的最新概念相统一。该共识基于截至 2010 年的现有建议，并将用于即将进行的 U-BIOPRED 研究中患者的选择。它包括区分“有问题的”、“困难的”和“严重难治的”哮喘，并提供了一种系统的算法方法来评估患有慢性严重哮喘症状的患者，用于临床研究和专门护理。
